Drug Trial Radar · NCT01064401
Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Jul 11, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,841
Actual
Start
May 2010
Primary completion
Mar 2014
Study completion Jul 2014
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- Collaborators
- AbbVie
- First posted
- Feb 8, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary study objective is to test the superiority of Daclizumab High Yield Process (DAC HYP) compared to interferon β 1a (IFN β-1a) in preventing multiple sclerosis (MS) relapse in participants with relapsing remitting multiple sclerosis. The secondary study objectives are to test the superiority of DAC HYP compared to IFN β-1a in slowing functional decline and disability progression and maintaining quality of life in this participant population.
Conditions
- Relapsing-Remitting Multiple Sclerosis
Interventions
BIIB019 (Daclizumab High Yield Process)Biological
Daclizumab High Yield Process for subcutaneous injection
Interferon beta-1a PlaceboDrug
Placebo to interferon beta-1a intramuscular injection
Interferon beta-1aBiological
Interferon beta-1a for intramuscular injection
Daclizumab High Yield Process PlaceboDrug
Placebo to Daclizumab High Yield Process subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adjusted Annualized Relapse Rate (ARR)Time frame: Up to 144 weeks
Locations
228 sites in 28 countries. Site status is shown where the registry gives one.
Research Site
Gilbert, Arizona
Research Site
Phoenix, Arizona
Research Site
Tucson, Arizona
Research Site
Little Rock, Arkansas
Research Site
La Jolla, California
Research Site
Aurora, Colorado
Research Site
Naples, Florida
Research Site
Pompano Beach, Florida
Research Site
St. Petersburg, Florida
Research Site
Sunrise, Florida
Research Site
Atlanta, Georgia
Research Site
Evanston, Illinois
Research Site
Fort Wayne, Indiana
Research Site
Indianapolis, Indiana
Research Site
Des Moines, Iowa
Research Site
Kansas City, Kansas
Research Site
Lexington, Kentucky
Research Site
Baltimore, Maryland
Research Site
Springfield, Massachusetts
Research Site
Worchester, Massachusetts
Research Site
Clinton Township, Michigan
Research Site
St Louis, Missouri
Research Site
Lebanon, New Hampshire
Research Site
New Brunswick, New Jersey
Research Site
Albuquerque, New Mexico
Research Site
Buffalo, New York
Research Site
Latham, New York
Research Site
New York, New York
Research Site
Rochester, New York
Research Site
Charlotte, North Carolina
Research Site
Raleigh, North Carolina
Research Site
Winston-Salem, North Carolina
Research Site
Medford, Oregon
Research Site
Portland, Oregon
Research Site
Allentown, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Pittsburgh, Pennsylvania
Research Site
Providence, Rhode Island
Research Site
Franklin, Tennessee
Research Site
Knoxville, Tennessee
Showing 40 of 228 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.